Eileen Turcott

1.1k total citations
7 papers, 860 citations indexed

About

Eileen Turcott is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Eileen Turcott has authored 7 papers receiving a total of 860 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Eileen Turcott's work include Monoclonal and Polyclonal Antibodies Research (3 papers), HER2/EGFR in Cancer Research (2 papers) and Glycosylation and Glycoproteins Research (1 paper). Eileen Turcott is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (3 papers), HER2/EGFR in Cancer Research (2 papers) and Glycosylation and Glycoproteins Research (1 paper). Eileen Turcott collaborates with scholars based in United States and Netherlands. Eileen Turcott's co-authors include James C. Geoghegan, Changpu Yu, John E. Skonier, David G. Winkler, John Latham, Charlotte F. McDonagh, Ivan J. Stone, May Kung Sutherland, David Morris and Paul Carter and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Bone.

In The Last Decade

Eileen Turcott

7 papers receiving 820 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eileen Turcott United States	7	550	348	249	95	94	7	860
M.V. Primavera Italy	7	365 0.7×	202 0.6×	27 0.1×	57 0.6×	43 0.5×	7	556
Chris K. Neeley United States	12	281 0.5×	467 1.3×	57 0.2×	13 0.1×	341 3.6×	13	849
Ganwei Lu United States	13	473 0.9×	222 0.6×	39 0.2×	14 0.1×	270 2.9×	17	799
Dick J. Schol Netherlands	11	473 0.9×	218 0.6×	195 0.8×	5 0.1×	152 1.6×	13	734
Christa Prange United States	8	648 1.2×	158 0.5×	21 0.1×	25 0.3×	81 0.9×	10	909
Xuemin Lu United States	9	353 0.6×	379 1.1×	38 0.2×	10 0.1×	173 1.8×	15	754
Christopher H. Chay United States	10	332 0.6×	316 0.9×	63 0.3×	6 0.1×	51 0.5×	26	737
Rajeshwari R. Valiathan United States	8	313 0.6×	250 0.7×	188 0.8×	5 0.1×	73 0.8×	10	722
Maurizio Fazio United States	11	433 0.8×	124 0.4×	85 0.3×	10 0.1×	54 0.6×	16	703
Sofia Sousa France	10	326 0.6×	399 1.1×	41 0.2×	10 0.1×	355 3.8×	15	843

Countries citing papers authored by Eileen Turcott

Since Specialization

Citations

This map shows the geographic impact of Eileen Turcott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eileen Turcott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eileen Turcott more than expected).

Fields of papers citing papers by Eileen Turcott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eileen Turcott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eileen Turcott. The network helps show where Eileen Turcott may publish in the future.

Co-authorship network of co-authors of Eileen Turcott

This figure shows the co-authorship network connecting the top 25 collaborators of Eileen Turcott. A scholar is included among the top collaborators of Eileen Turcott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eileen Turcott. Eileen Turcott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

McDonagh, Charlotte F., Kristine M. Kim, Eileen Turcott, et al.. (2008). Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Molecular Cancer Therapeutics. 7(9). 2913–2923. 60 indexed citations

2.

McDonagh, Charlotte F., Eileen Turcott, Lori Westendorf, et al.. (2006). Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Engineering Design and Selection. 19(7). 299–307. 182 indexed citations

3.

McEarchern, Julie A., Ezogelin Oflazoglu, Leigh Francisco, et al.. (2006). Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood. 109(3). 1185–1192. 87 indexed citations

4.

Sutherland, May Kung, James C. Geoghegan, Changpu Yu, et al.. (2004). Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 35(4). 828–835. 180 indexed citations

5.

Winkler, David G., May S.K. Sutherland, Ethan W. Ojala, et al.. (2004). Sclerostin Inhibition of Wnt-3a-induced C3H10T1/2 Cell Differentiation Is Indirect and Mediated by Bone Morphogenetic Proteins. Journal of Biological Chemistry. 280(4). 2498–2502. 139 indexed citations

6.

MacKay, Vivian L., Xiaohong Li, Mark R. Flory, et al.. (2004). Gene Expression Analyzed by High-resolution State Array Analysis and Quantitative Proteomics. Molecular & Cellular Proteomics. 3(5). 478–489. 149 indexed citations

7.

Jin, Xiaoping, et al.. (2003). The Two Upstream Open Reading Frames of Oncogene mdm2 Have Different Translational Regulatory Properties. Journal of Biological Chemistry. 278(28). 25716–25721. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact